ArticleJournal of investigative medicine high impact case reports
Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease: A Report of 2 Patient Cases.
Article in Journal of investigative medicine high impact case reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Immune Checkpoint Inhibitors in Patients with Pre-existing Neurologic Autoimmune Disorders.Current neurology and neuroscience reports · 2023Review
- An overview of the efficacy of phototherapy in oncodermatology.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Review
- Association Between Clinical Factors and Result of Immune Checkpoint Inhibitor Related Myasthenia Gravis: A Single Center Experience and Systematic Review.Frontiers in neurology · 2022Article
- Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.Journal for immunotherapy of cancer · 2021Article
- Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases.Mediterranean journal of rheumatology · 2021Review
- Myasthenia gravis induced or exacerbated by immune checkpoint inhibitors: a rising concern.BMJ case reports · 2021Article
- Immunotherapy use outside clinical trial populations: never say never?Annals of oncology : official journal of the European Society for Medical Oncology · 2021Review
- Dermatologic Toxicities of Targeted Therapy and Immunotherapy in Head and Neck Cancers.Frontiers in oncology · 2021Review
- Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review.Dermatology practical & conceptual · 2021Review
- Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease.Cancer management and research · 2021Review
- Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis.eNeurologicalSci · 2020Article
- Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy.Current oncology (Toronto, Ont.) · 2020Review
- Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders.Frontiers in medicine · 2020Review
- Immune Checkpoint Inhibitor-Induced Myasthenia Gravis.Frontiers in neurology · 2020Review
- Melanoma and Vitiligo: In Good Company.International journal of molecular sciences · 2019Review
- Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer.Respirology case reports · 2018Article
- Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.Current neurology and neuroscience reports · 2018Review
- [Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2018Article
- Cutaneous CD56JAAD case reports · 2018Article
- Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report.Investigational new drugs · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Historically, metastatic melanoma was uniformly and rapidly lethal, and treatment options were limited. In recent years, however, checkpoint inhibitors have emerged as an accepted standard treatment for patients with advanced melanoma. In clinical trials, these agents have been largely well tolerated and have the potential to result in durable responses. Importantly though, one must recognize the unique side effect profile of these therapies, which can trigger or exacerbate underlying autoimmune disease. Whether this autoimmune activation is associated with a clinical response to therapy has been debated, and while not definitive, there is evidence in the literature of a possible association. The 2 cases presented describe this autoimmune phenomenon, along with a review of the existing literature on the relationship between response to immunotherapy and autoimmune side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.